Akebia Therapeutics (AKBA) Depreciation & Amortization (CF) (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Depreciation & Amortization (CF) of $328000.0 for Q1 2026, up 4.46% year-over-year from $314000.0 in Q1 2025, and up 2.18% quarter-over-quarter from $321000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $328000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 4.46% year-over-year to $328000.0; the TTM figure through Mar 2026 stood at $1.3 million (down 9.14% YoY), while the FY2025 annual figure was $1.3 million, down 13.2% from the prior year.
- Depreciation & Amortization (CF) climbed to $328000.0 in Q1 2026 per AKBA's latest filing, from $321000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $417000.0 in Q1 2022 and bottomed at $314000.0 in Q1 2025.
- Historically, Depreciation & Amortization (CF) has averaged $370470.6 across 5 years, with a median of $394000.0 in 2023.
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) fell 21.0% — and 2026, when it climbed 4.46%.
- Akebia Therapeutics' Depreciation & Amortization (CF) stood at $408000.0 in 2022, then declined by 3.43% to $394000.0 in 2023, then dropped by 14.97% to $335000.0 in 2024, then declined by 4.18% to $321000.0 in 2025, then rose by 2.18% to $328000.0 in 2026.
- Business Quant data shows AKBA's Depreciation & Amortization (CF) at $328000.0 in Q1 2026, $321000.0 in Q4 2025, and $318000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Akebia Therapeutics | 247.98 Mn | 92.43 Mn | 38.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 585,000.00 |
| Jun 30, 2026 | 585,000.00 |
| Mar 31, 2026 | 328,000.00 |
| Mar 31, 2026 | 328,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Jun 30, 2025 | 316,000.00 |
| Jun 30, 2025 | 316,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Dec 31, 2024 | 335,000.00 |
| Dec 31, 2024 | 335,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 364,000.00 |
| Mar 31, 2024 | 364,000.00 |